Raad 1996.

Methods	RCT Outcome assessor blinded 1993‐1994
Participants	Number: 390 patients Age: imipenem med 52 range (17‐82); aztreonam 48 (18‐81)
Interventions	Imipenem 500mgX4 + vancomycin 1grX2 versus Aztreonam 2grX4 + vancomycin 1grX2
Outcomes	All‐cause and infection‐related mortality Clinical and microbiological failure Bacterial and fungal superinfections Adverse events
Notes	USA
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Low risk	Computer generated sequence
Allocation concealment?	Low risk	Central in hospital's pharmacy, treatment assignment unknown to investigator in charge of determining eligibility
Blinding? All outcomes	High risk	Only outcome assessor blinded
Incomplete outcome data addressed? All‐cause mortality	High risk	23% dropouts
Incomplete outcome data addressed? Treatment failure	High risk	23% dropouts
Free of other bias?	Low risk